Protein Biosynthesis Interference in Disease

Features:

• Enables biochemists, molecular biologists and disease researchers to advance disease prevention, laboratory testing, and treatment pathways for protein biosynthesis interference related disorders
• Examines the biochemical and molecular basis of protein biosynthesis interference in neurodegenerative disorders, cancer and inflammatory conditions, among other diseases
• Analyzes tryptamine, biogenic amines, and aminoacyl-tRNA synthetases dynamics in protein translation and possible treatment pathways regulating protein biosynthesis

Table of Contents:

1. Introduction
2. Tryptamine in the diet, human microbiome, tRNA aminoacylation-protein biosynthesis, host-microbiota metabolic interactions
3. Dimethyltryptamine, methyltryptamine, hallucinations and metals
4. Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT) and N, N-dimethyltryptamine (DMT): quantification methods
5. Tryptamine in renal pathologies and in pregnancy
6. Tryptophanyl-tRNA synthetase (TrpRS) inhibition or TrpRS gene (WARS) mutations and deletion result to TrpRS deficiency and pathologies
7. Tryptamine in liver diseases and alcohol abuse
8. Tryptamine and tyramine in tobacco smoking
9. Tryptamine and other biogenic amines in human vaginal samples
10. Tryptamine and tryptophan in human fecal samples: diet alters tryptamine levels
11. Tryptamine in human noncataractous and cataractous eye lenses
12. Tryptamine toxicity in rats, adrenalectomy, toxicity prevention
13. Microorganisms: the natural producers of tryptamine in food
14. Human gut bacterial sequence associated with Alzheimer’s disease and biogenic amines
15. Disease, factors and condition associated with Alzheimer’s disease (AD) and dementia support a concept that AD is a widespread systemic disorder
16. Arterial hypertension in comorbidity in dementia and Alzheimer’s disease, tryptamine in metabolic syndrome
17. Whole blood viscosity: biogenic amines, dementia and Alzheimer’s disease
18. Tryptamine and aminoacyl-tRNAs in sleep-wake and circadian disruptions
19. Senile plaques and/or neurofibrillary tangles in brain of non-demented individuals
20. Historical perspectives and future research directions
21. Tryptamine content and effects in humans and animals
22. Link protein half-lives to neurodegeneration: tryptamine treatment effects
23. Alzheimer’s disease human gut microbiome associated sequence (ADAS): predictive disease modeling with ADAS: generating ADAS variants from human samples
24. Tryptamine and other biogenic amines (BA) as modified and degradable factors
25. Tryptamine and TrpRS in cancer and other conditions
26. Experimental procedures: tryptophanyl-tRNA synthetase (TrpRS) characterization
27. Tryptophanyl-tRNA synthetase (TrpRS) in phosphosignaling
28. Tryptophanyl-tRNA synthetase antigenic epitopes and mimotpes
29. Interactomes: tryptophanyl-tRNA synthetase forms and other aminoacyl-tRNA synthetases
30. Tryptophanyl-tRNA synthetase in cell and organism survival
31. Tryptophanyl-tRNA synthetase sharing epitopes
32. Tryptamine and Tryptophanyl-tRNA synthetase in microvesicles, multivesicular bodies, and exosomes
33. Tryptophanyl-tRNA synthetase and tryptamine in protein kinase and cancer pathways
34. Global protein biosynthesis and aminoacyl-tRNA synthetase family